coramaze technologies GmbH, an Essen, Germany-based medical device company focused on treatment of heart valve diseases, raised €1m in funding.
The company intends to use the funds to advance the pre-clinical development of its mitramaze® valve repair system to treat mitral regurgitation in patient segments that cannot undergo standard cardiac surgery.
Founded in 2013 as a spin-off from the Western German Heart Center by CEO Dr. Laura Figulla and Prof. Dr. Till Neumann, coramaze technologies is developing a medical device for the minimally invasive treatment of mitral regurgitation.
The mitramaze® valve repair system technology, which has been developed through a technological research project funded by the EXIST research transfer of the German Federal Ministry of Economics and Technology, enables an atraumatic insertion and positioning within the patient’s heart without the risk of dislocation. It can also be used for the treatment of other structural heart valve diseases, such as tricuspid regurgitation.